These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26154003)

  • 1. The constrained prescription, interchangeability and substitution of biosimilars.
    Minghetti P; Rocco P; Schellekens H
    Nat Biotechnol; 2015 Jul; 33(7):688-9. PubMed ID: 26154003
    [No Abstract]   [Full Text] [Related]  

  • 2. Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.
    Druedahl LC; Kälvemark Sporrong S; Minssen T; Hoogland H; De Bruin ML; van de Weert M; Almarsdóttir AB
    PLoS One; 2022; 17(1):e0262537. PubMed ID: 35015783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Expectations for Demonstrating Interchangeability.
    Chance K
    Ther Innov Regul Sci; 2018 May; 52(3):369-373. PubMed ID: 29714562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable.
    Afzali A; Furtner D; Melsheimer R; Molloy PJ
    Adv Ther; 2021 May; 38(5):2077-2093. PubMed ID: 33745111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interchangeability Of Biological Drug Products-FDA Draft Guidance.
    Endrenyi L; Markus R
    J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotech innovators jump on biosimilars bandwagon.
    Moran N
    Nat Biotechnol; 2012 Apr; 30(4):297-9. PubMed ID: 22491261
    [No Abstract]   [Full Text] [Related]  

  • 8. [Interchangeability and substitution of biosimilars].
    Astier A
    Ann Pharm Fr; 2020 Jul; 78(4):277-284. PubMed ID: 32387176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparability conundrum: biosimilars in the United States, Europe and Canada.
    Courage N; Parsons A
    Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Current State of Dermatologists' Familiarity and Perspectives of Biosimilars for the Treatment of Psoriasis: A Global Cross-Sectional Survey.
    Manalo IF; Gilbert KE; Wu JJ
    J Drugs Dermatol; 2017 Apr; 16(4):336-343. PubMed ID: 28403267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Science of Biosimilars-Updating Interchangeability.
    Cavazzoni P; Yim S
    JAMA; 2024 Oct; 332(15):1235-1236. PubMed ID: 39292484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars battle rages on, Amgen fights both sides.
    Senior M
    Nat Biotechnol; 2013 Apr; 31(4):269-70. PubMed ID: 23563402
    [No Abstract]   [Full Text] [Related]  

  • 13. First monoclonal antibody biosimilars: tackling the challenge of substitution.
    Bocquet F; Paubel P
    J Med Econ; 2016 Jun; 19(6):645-7. PubMed ID: 27080815
    [No Abstract]   [Full Text] [Related]  

  • 14. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars and the European experience: implications for the United States.
    Megerlin F; Lopert R; Taymor K; Trouvin JH
    Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indiana jumps the biosimilars gun.
    Fox JL
    Nat Biotechnol; 2014 May; 32(5):406. PubMed ID: 24811502
    [No Abstract]   [Full Text] [Related]  

  • 19. On the interchangeability of biologic drug products.
    Endrenyi L; Chang C; Chow SC; Tothfalusi L
    Stat Med; 2013 Feb; 32(3):434-41. PubMed ID: 22911936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction and commentary: Paving the way for biosimilars in oncology, part 3: Clinical and economic impact of oncology biosimilars.
    Abraham J
    Semin Oncol; 2014 Apr; 41 Suppl 3():S1-2. PubMed ID: 24767631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.